ID   GFPT1_HUMAN             Reviewed;         699 AA.
AC   Q06210; Q53QE6; Q9BXF8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   12-APR-2017, entry version 171.
DE   RecName: Full=Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1;
DE            EC=2.6.1.16 {ECO:0000250|UniProtKB:P82808};
DE   AltName: Full=D-fructose-6-phosphate amidotransferase 1;
DE   AltName: Full=Glutamine:fructose-6-phosphate amidotransferase 1;
DE            Short=GFAT 1;
DE            Short=GFAT1;
DE   AltName: Full=Hexosephosphate aminotransferase 1;
GN   Name=GFPT1; Synonyms=GFAT, GFPT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1460020;
RA   McKnight G.L., Mudri S.L., Mathewes S.L., Traxinger R.R., Marshall S.,
RA   Sheppard P.O., O'Hara P.J.;
RT   "Molecular cloning, cDNA sequence, and bacterial expression of human
RT   glutamine:fructose-6-phosphate amidotransferase.";
RL   J. Biol. Chem. 267:25208-25212(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 124-275 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11679416; DOI=10.2337/diabetes.50.11.2419;
RA   DeHaven J.E., Robinson K.A., Nelson B.A., Buse M.G.;
RT   "A novel variant of glutamine:fructose-6-phosphate amidotransferase-1
RT   (GFAT1) mRNA is selectively expressed in striated muscle.";
RL   Diabetes 50:2419-2424(2001).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-261, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-261, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-261, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103 AND SER-261, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-261, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17] {ECO:0000244|PDB:2ZJ3, ECO:0000244|PDB:2ZJ4}
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 332-699, SUBUNIT, AND
RP   SUBSTRATE-BINDING SITES.
RX   PubMed=19059404; DOI=10.1016/j.febslet.2008.11.041;
RA   Nakaishi Y., Bando M., Shimizu H., Watanabe K., Goto F., Tsuge H.,
RA   Kondo K., Komatsu M.;
RT   "Structural analysis of human glutamine:fructose-6-phosphate
RT   amidotransferase, a key regulator in type 2 diabetes.";
RL   FEBS Lett. 583:163-167(2009).
RN   [18]
RP   VARIANTS CMS12 ALA-15; MET-15; VAL-43; CYS-111; THR-121; PHE-199;
RP   TYR-366; HIS-403; HIS-452; THR-509; THR-510; TRP-514 AND TRP-530.
RX   PubMed=21310273; DOI=10.1016/j.ajhg.2011.01.008;
RA   Senderek J., Muller J.S., Dusl M., Strom T.M., Guergueltcheva V.,
RA   Diepolder I., Laval S.H., Maxwell S., Cossins J., Krause S.,
RA   Muelas N., Vilchez J.J., Colomer J., Mallebrera C.J., Nascimento A.,
RA   Nafissi S., Kariminejad A., Nilipour Y., Bozorgmehr B., Najmabadi H.,
RA   Rodolico C., Sieb J.P., Steinlein O.K., Schlotter B., Schoser B.,
RA   Kirschner J., Herrmann R., Voit T., Oldfors A., Lindbergh C.,
RA   Urtizberea A., von der Hagen M., Hubner A., Palace J., Bushby K.,
RA   Straub V., Beeson D., Abicht A., Lochmuller H.;
RT   "Hexosamine biosynthetic pathway mutations cause neuromuscular
RT   transmission defect.";
RL   Am. J. Hum. Genet. 88:162-172(2011).
CC   -!- FUNCTION: Controls the flux of glucose into the hexosamine
CC       pathway. Most likely involved in regulating the availability of
CC       precursors for N- and O-linked glycosylation of proteins.
CC       Regulates the circadian expression of clock genes ARNTL/BMAL1 and
CC       CRY1.
CC   -!- CATALYTIC ACTIVITY: L-glutamine + D-fructose 6-phosphate = L-
CC       glutamate + D-glucosamine 6-phosphate.
CC       {ECO:0000250|UniProtKB:P82808}.
CC   -!- PATHWAY: Nucleotide-sugar biosynthesis; UDP-N-acetyl-alpha-D-
CC       glucosamine biosynthesis; alpha-D-glucosamine 6-phosphate from D-
CC       fructose 6-phosphate: step 1/1. {ECO:0000250|UniProtKB:P82808}.
CC   -!- SUBUNIT: Homotetramer (Probable), may also exist as homodimers.
CC       {ECO:0000269|PubMed:19059404}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=GFAT1m;
CC         IsoId=Q06210-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q06210-2; Sequence=VSP_007497;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is predominantly expressed in
CC       skeletal muscle. Not expressed in brain. Seems to be selectively
CC       expressed in striated muscle. {ECO:0000269|PubMed:11679416}.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 12 (CMS12) [MIM:610542]:
CC       A form of congenital myasthenic syndrome, a group of disorders
CC       characterized by failure of neuromuscular transmission, including
CC       pre-synaptic, synaptic, and post-synaptic disorders that are not
CC       of autoimmune origin. Clinical features are easy fatigability and
CC       muscle weakness. CMS12 is characterized by onset of proximal
CC       muscle weakness in the first decade. Individuals with this
CC       condition have a recognizable pattern of weakness of shoulder and
CC       pelvic girdle muscles, and sparing of ocular or facial muscles.
CC       EMG classically shows a decremental response to repeated nerve
CC       stimulation, a sign of neuromuscular junction dysfunction.
CC       Affected individuals show a favorable response to
CC       acetylcholinesterase (AChE) inhibitors.
CC       {ECO:0000269|PubMed:21310273}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M90516; AAA58502.1; -; mRNA.
DR   EMBL; AC114772; AAY14827.1; -; Genomic_DNA.
DR   EMBL; BC045641; AAH45641.1; -; mRNA.
DR   EMBL; AF334737; AAK15342.1; -; mRNA.
DR   CCDS; CCDS33216.1; -. [Q06210-2]
DR   CCDS; CCDS58713.1; -. [Q06210-1]
DR   PIR; A45055; A45055.
DR   RefSeq; NP_001231639.1; NM_001244710.1. [Q06210-1]
DR   RefSeq; NP_002047.2; NM_002056.3. [Q06210-2]
DR   UniGene; Hs.580300; -.
DR   PDB; 2V4M; X-ray; 2.29 A; A/B/C/D=332-699.
DR   PDB; 2ZJ3; X-ray; 1.90 A; A=332-699.
DR   PDB; 2ZJ4; X-ray; 2.20 A; A=332-699.
DR   PDBsum; 2V4M; -.
DR   PDBsum; 2ZJ3; -.
DR   PDBsum; 2ZJ4; -.
DR   ProteinModelPortal; Q06210; -.
DR   SMR; Q06210; -.
DR   BioGrid; 108941; 58.
DR   IntAct; Q06210; 11.
DR   MINT; MINT-5001216; -.
DR   STRING; 9606.ENSP00000354347; -.
DR   BindingDB; Q06210; -.
DR   ChEMBL; CHEMBL1909481; -.
DR   MEROPS; C44.970; -.
DR   iPTMnet; Q06210; -.
DR   PhosphoSitePlus; Q06210; -.
DR   SwissPalm; Q06210; -.
DR   BioMuta; GFPT1; -.
DR   DMDM; 30923274; -.
DR   EPD; Q06210; -.
DR   MaxQB; Q06210; -.
DR   PaxDb; Q06210; -.
DR   PeptideAtlas; Q06210; -.
DR   PRIDE; Q06210; -.
DR   Ensembl; ENST00000357308; ENSP00000349860; ENSG00000198380. [Q06210-1]
DR   Ensembl; ENST00000361060; ENSP00000354347; ENSG00000198380. [Q06210-2]
DR   GeneID; 2673; -.
DR   KEGG; hsa:2673; -.
DR   UCSC; uc002sfh.4; human. [Q06210-1]
DR   CTD; 2673; -.
DR   DisGeNET; 2673; -.
DR   GeneCards; GFPT1; -.
DR   GeneReviews; GFPT1; -.
DR   HGNC; HGNC:4241; GFPT1.
DR   HPA; HPA047240; -.
DR   MalaCards; GFPT1; -.
DR   MIM; 138292; gene.
DR   MIM; 610542; phenotype.
DR   neXtProt; NX_Q06210; -.
DR   OpenTargets; ENSG00000198380; -.
DR   Orphanet; 353327; Congenital myasthenic syndromes with glycosylation defect.
DR   PharmGKB; PA28651; -.
DR   eggNOG; KOG1268; Eukaryota.
DR   eggNOG; COG0449; LUCA.
DR   GeneTree; ENSGT00390000010049; -.
DR   HOGENOM; HOG000258898; -.
DR   HOVERGEN; HBG051724; -.
DR   InParanoid; Q06210; -.
DR   KO; K00820; -.
DR   OMA; MYDNRDS; -.
DR   OrthoDB; EOG091G02N5; -.
DR   PhylomeDB; Q06210; -.
DR   TreeFam; TF300864; -.
DR   BioCyc; MetaCyc:HS09974-MONOMER; -.
DR   BRENDA; 2.6.1.16; 2681.
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes.
DR   Reactome; R-HSA-446210; Synthesis of UDP-N-acetyl-glucosamine.
DR   SIGNOR; Q06210; -.
DR   UniPathway; UPA00113; UER00528.
DR   ChiTaRS; GFPT1; human.
DR   EvolutionaryTrace; Q06210; -.
DR   GeneWiki; GFPT1; -.
DR   GenomeRNAi; 2673; -.
DR   PRO; PR:Q06210; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000198380; -.
DR   CleanEx; HS_GFPT1; -.
DR   Genevisible; Q06210; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0097367; F:carbohydrate derivative binding; IEA:InterPro.
DR   GO; GO:0004360; F:glutamine-fructose-6-phosphate transaminase (isomerizing) activity; TAS:Reactome.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:ProtInc.
DR   GO; GO:0006002; P:fructose 6-phosphate metabolic process; TAS:ProtInc.
DR   GO; GO:0006541; P:glutamine metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0006048; P:UDP-N-acetylglucosamine biosynthetic process; TAS:Reactome.
DR   Gene3D; 3.60.20.10; -; 1.
DR   InterPro; IPR017932; GATase_2_dom.
DR   InterPro; IPR005855; GlmS_trans.
DR   InterPro; IPR029055; Ntn_hydrolases_N.
DR   InterPro; IPR001347; SIS.
DR   Pfam; PF01380; SIS; 2.
DR   SUPFAM; SSF56235; SSF56235; 2.
DR   TIGRFAMs; TIGR01135; glmS; 1.
DR   PROSITE; PS51278; GATASE_TYPE_2; 1.
DR   PROSITE; PS51464; SIS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aminotransferase;
KW   Biological rhythms; Complete proteome; Congenital myasthenic syndrome;
KW   Disease mutation; Glutamine amidotransferase; Phosphoprotein;
KW   Reference proteome; Repeat; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000250}.
FT   CHAIN         2    699       Glutamine--fructose-6-phosphate
FT                                aminotransferase [isomerizing] 1.
FT                                /FTId=PRO_0000135280.
FT   DOMAIN        2    305       Glutamine amidotransferase type-2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00609}.
FT   DOMAIN      377    516       SIS 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00797}.
FT   DOMAIN      548    689       SIS 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00797}.
FT   REGION      313    680       Isomerase.
FT   REGION      394    395       Substrate-binding. {ECO:0000244|PDB:2V4M,
FT                                ECO:0000244|PDB:2ZJ3,
FT                                ECO:0000244|PDB:2ZJ4,
FT                                ECO:0000269|PubMed:19059404}.
FT   REGION      439    441       Substrate-binding. {ECO:0000244|PDB:2V4M,
FT                                ECO:0000244|PDB:2ZJ3,
FT                                ECO:0000244|PDB:2ZJ4,
FT                                ECO:0000269|PubMed:19059404}.
FT   ACT_SITE      2      2       For GATase activity.
FT                                {ECO:0000250|UniProtKB:P14742}.
FT   BINDING     444    444       Substrate. {ECO:0000244|PDB:2V4M,
FT                                ECO:0000244|PDB:2ZJ3,
FT                                ECO:0000244|PDB:2ZJ4,
FT                                ECO:0000269|PubMed:19059404}.
FT   BINDING     595    595       Substrate. {ECO:0000244|PDB:2V4M,
FT                                ECO:0000244|PDB:2ZJ3,
FT                                ECO:0000244|PDB:2ZJ4,
FT                                ECO:0000269|PubMed:19059404}.
FT   MOD_RES     103    103       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     261    261       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ     229    246       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1460020,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007497.
FT   VARIANT      15     15       T -> A (in CMS12; dbSNP:rs387906638).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065339.
FT   VARIANT      15     15       T -> M (in CMS12; dbSNP:rs751097758).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065340.
FT   VARIANT      43     43       D -> V (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065341.
FT   VARIANT     111    111       R -> C (in CMS12; dbSNP:rs201322234).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065342.
FT   VARIANT     121    121       I -> T (in CMS12; dbSNP:rs753866967).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065343.
FT   VARIANT     199    199       V -> F (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065344.
FT   VARIANT     366    366       D -> Y (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065345.
FT   VARIANT     403    403       R -> H (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065346.
FT   VARIANT     452    452       R -> H (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065347.
FT   VARIANT     509    509       M -> T (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065348.
FT   VARIANT     510    510       M -> T (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065349.
FT   VARIANT     514    514       R -> W (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065350.
FT   VARIANT     530    530       R -> W (in CMS12).
FT                                {ECO:0000269|PubMed:21310273}.
FT                                /FTId=VAR_065351.
FT   STRAND      339    341       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       342    348       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       350    358       {ECO:0000244|PDB:2ZJ3}.
FT   TURN        359    361       {ECO:0000244|PDB:2ZJ3}.
FT   TURN        364    367       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       372    374       {ECO:0000244|PDB:2ZJ3}.
FT   TURN        375    377       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       378    383       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      385    391       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       393    410       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      414    418       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       419    424       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      433    442       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       445    456       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      460    466       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       471    475       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      476    481       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      489    491       {ECO:0000244|PDB:2ZJ4}.
FT   HELIX       494    510       {ECO:0000244|PDB:2ZJ3}.
FT   TURN        511    513       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       515    517       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       518    539       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       542    552       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      556    562       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       564    566       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       567    581       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      584    589       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       590    595       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       597    600       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      602    605       {ECO:0000244|PDB:2V4M}.
FT   STRAND      607    611       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       617    629       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      635    639       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       643    648       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      650    655       {ECO:0000244|PDB:2ZJ3}.
FT   TURN        660    662       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       663    667       {ECO:0000244|PDB:2ZJ3}.
FT   HELIX       669    681       {ECO:0000244|PDB:2ZJ3}.
FT   STRAND      686    688       {ECO:0000244|PDB:2ZJ3}.
SQ   SEQUENCE   699 AA;  78806 MW;  F0533A7B762C7B98 CRC64;
     MCGIFAYLNY HVPRTRREIL ETLIKGLQRL EYRGYDSAGV GFDGGNDKDW EANACKIQLI
     KKKGKVKALD EEVHKQQDMD LDIEFDVHLG IAHTRWATHG EPSPVNSHPQ RSDKNNEFIV
     IHNGIITNYK DLKKFLESKG YDFESETDTE TIAKLVKYMY DNRESQDTSF TTLVERVIQQ
     LEGAFALVFK SVHFPGQAVG TRRGSPLLIG VRSEHKLSTD HIPILYRTAR TQIGSKFTRW
     GSQGERGKDK KGSCNLSRVD STTCLFPVEE KAVEYYFASD ASAVIEHTNR VIFLEDDDVA
     AVVDGRLSIH RIKRTAGDHP GRAVQTLQME LQQIMKGNFS SFMQKEIFEQ PESVVNTMRG
     RVNFDDYTVN LGGLKDHIKE IQRCRRLILI ACGTSYHAGV ATRQVLEELT ELPVMVELAS
     DFLDRNTPVF RDDVCFFLSQ SGETADTLMG LRYCKERGAL TVGITNTVGS SISRETDCGV
     HINAGPEIGV ASTKAYTSQF VSLVMFALMM CDDRISMQER RKEIMLGLKR LPDLIKEVLS
     MDDEIQKLAT ELYHQKSVLI MGRGYHYATC LEGALKIKEI TYMHSEGILA GELKHGPLAL
     VDKLMPVIMI IMRDHTYAKC QNALQQVVAR QGRPVVICDK EDTETIKNTK RTIKVPHSVD
     CLQGILSVIP LQLLAFHLAV LRGYDVDFPR NLAKSVTVE
//
